130 related articles for article (PubMed ID: 8318875)
1. Relationship between patient response in ovarian and breast cancer and platinum drug-DNA adduct formation.
Gupta-Burt S; Shamkhani H; Reed E; Tarone RE; Allegra CJ; Pai LH; Poirier MC
Cancer Epidemiol Biomarkers Prev; 1993; 2(3):229-34. PubMed ID: 8318875
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of platinum-DNA adduct levels relative to known prognostic variables in a cohort of ovarian cancer patients.
Reed E; Ostchega Y; Steinberg SM; Yuspa SH; Young RC; Ozols RF; Poirier MC
Cancer Res; 1990 Apr; 50(8):2256-60. PubMed ID: 2180564
[TBL] [Abstract][Full Text] [Related]
3. Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy.
Bonetti A; Apostoli P; Zaninelli M; Pavanel F; Colombatti M; Cetto GL; Franceschi T; Sperotto L; Leone R
Clin Cancer Res; 1996 Nov; 2(11):1829-35. PubMed ID: 9816137
[TBL] [Abstract][Full Text] [Related]
4. Persistence of platinum-ammine-DNA adducts in gonads and kidneys of rats and multiple tissues from cancer patients.
Poirier MC; Reed E; Litterst CL; Katz D; Gupta-Burt S
Cancer Res; 1992 Jan; 52(1):149-53. PubMed ID: 1727376
[TBL] [Abstract][Full Text] [Related]
5. DNA adducts of cisplatin and carboplatin in tissues of cancer patients.
Poirier MC; Egorin MJ; Fichtinger-Schepman AM; Yuspa SH; Reed E
IARC Sci Publ; 1988; (89):313-20. PubMed ID: 3058599
[TBL] [Abstract][Full Text] [Related]
6. Quantitation of cis-diamminedichloroplatinum II (cisplatin)-DNA-intrastrand adducts in testicular and ovarian cancer patients receiving cisplatin chemotherapy.
Reed E; Yuspa SH; Zwelling LA; Ozols RF; Poirier MC
J Clin Invest; 1986 Feb; 77(2):545-50. PubMed ID: 3944268
[TBL] [Abstract][Full Text] [Related]
7. Drug-induced DNA modification in buccal cells of cancer patients receiving carboplatin and cisplatin combination chemotherapy, as determined by an immunocytochemical method: interindividual variation and correlation with disease response.
Blommaert FA; Michael C; Terheggen PM; Muggia FM; Kortes V; Schornagel JH; Hart AA; den Engelse L
Cancer Res; 1993 Dec; 53(23):5669-75. PubMed ID: 8242622
[TBL] [Abstract][Full Text] [Related]
8. Kinetics of the formation and removal of cisplatin-DNA adducts in blood cells and tumor tissue of cancer patients receiving chemotherapy: comparison with in vitro adduct formation.
Fichtinger-Schepman AM; van der Velde-Visser SD; van Dijk-Knijnenburg HC; van Oosterom AT; Baan RA; Berends F
Cancer Res; 1990 Dec; 50(24):7887-94. PubMed ID: 2253228
[TBL] [Abstract][Full Text] [Related]
9. A Gynecologic Oncology Group study of platinum-DNA adducts and excision repair cross-complementation group 1 expression in optimal, stage III epithelial ovarian cancer treated with platinum-taxane chemotherapy.
Darcy KM; Tian C; Reed E
Cancer Res; 2007 May; 67(9):4474-81. PubMed ID: 17483363
[TBL] [Abstract][Full Text] [Related]
10. Platinum-DNA adducts assayed in leukocytes of patients with germ cell tumors measured by atomic absorbance spectrometry and enzyme-linked immunosorbent assay.
Motzer RJ; Reed E; Perera F; Tang D; Shamkhani H; Poirier MC; Tsai WY; Parker RJ; Bosl GJ
Cancer; 1994 Jun; 73(11):2843-52. PubMed ID: 7514956
[TBL] [Abstract][Full Text] [Related]
11. Influence of cellular factors and pharmacokinetics on the formation of platinum-DNA adducts in leukocytes of children receiving cisplatin therapy.
Veal GJ; Dias C; Price L; Parry A; Errington J; Hale J; Pearson AD; Boddy AV; Newell DR; Tilby MJ
Clin Cancer Res; 2001 Aug; 7(8):2205-12. PubMed ID: 11489793
[TBL] [Abstract][Full Text] [Related]
12. Relationship between platinum-DNA adducts in leukocytes of patients with advanced germ cell cancer and survival.
Fisch MJ; Howard KL; Einhorn LH; Sledge GW
Clin Cancer Res; 1996 Jun; 2(6):1063-6. PubMed ID: 9816268
[TBL] [Abstract][Full Text] [Related]
13. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.
Levesque MA; Katsaros D; Massobrio M; Genta F; Yu H; Richiardi G; Fracchioli S; Durando A; Arisio R; Diamandis EP
Clin Cancer Res; 2000 Aug; 6(8):3260-70. PubMed ID: 10955812
[TBL] [Abstract][Full Text] [Related]
14. cis-Diamminedichloroplatinum (II)-DNA adduct formation in renal, gonadal, and tumor tissues of male and female rats.
Reed E; Litterst CL; Thill CC; Yuspa SH; Poirier MC
Cancer Res; 1987 Feb; 47(3):718-22. PubMed ID: 3802077
[TBL] [Abstract][Full Text] [Related]
15. Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small-volume residual ovarian cancer.
Markman M; Reichman B; Hakes T; Rubin S; Lewis JL; Jones W; Barakat R; Curtin J; Almadrones L; Hoskins W
Gynecol Oncol; 1993 Jul; 50(1):100-4. PubMed ID: 8349150
[TBL] [Abstract][Full Text] [Related]
16. Platinum drug-DNA interactions in human tissues measured by cisplatin-DNA enzyme-linked immunosorbent assay and atomic absorbance spectroscopy.
Poirier MC; Reed E; Shamkhani H; Tarone RE; Gupta-Burt S
Environ Health Perspect; 1993 Mar; 99():149-54. PubMed ID: 8319613
[TBL] [Abstract][Full Text] [Related]
17. Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy.
Reed E; Ozols RF; Tarone R; Yuspa SH; Poirier MC
Proc Natl Acad Sci U S A; 1987 Jul; 84(14):5024-8. PubMed ID: 3110781
[TBL] [Abstract][Full Text] [Related]
18. Platinum-DNA damage in leukocyte DNA of patients receiving carboplatin and cisplatin chemotherapy, measured by atomic absorption spectrometry.
Parker RJ; Gill I; Tarone R; Vionnet JA; Grunberg S; Muggia FM; Reed E
Carcinogenesis; 1991 Jul; 12(7):1253-8. PubMed ID: 2070490
[TBL] [Abstract][Full Text] [Related]
19. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
20. Characterization of the DNA damage recognized by an antiserum elicited against cis-diamminedichloroplatinum (II)-modified DNA.
Reed E; Gupta-Burt S; Litterst CL; Poirier MC
Carcinogenesis; 1990 Dec; 11(12):2117-21. PubMed ID: 1979937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]